Background and rationale {6a}
chemotherapy-induced neuropathy, peripheral neuropathy, seizures, neuropathy
ONCOLOGY, PERIPHERAL NEUROPATHY, POST-HERPETIC NEURALGIA, NEUROPATHY
In 1967, Monroe E. Wall reported in vitro broad spectrum anti-neoplastic activity of crude extracts from barks of Patients who develop paclitaxel-induced peripheral neuropathy present with sensory symptoms in a glove and stocking pattern [The American Society of Clinical Oncology (ASCO) guidelines note the lack of effective interventions for preventing chemotherapy-induced neuropathy. While some interventions demonstrated promising activity in early phase trials, no agent has been found to be effective in a subsequent phase III trial [Gabapentin is a structural analog of the neurotransmitter gamma-aminobutyric acid (GABA) and binds with high affinity to the α2δ subunit of the voltage-gated calcium channels. It is approved for the management of focal onset seizures (adults and pediatric patients aged 3 years or more) and post-herpetic neuralgia (adults only) [Gabapentin may prevent paclitaxel-induced neuropathy by inhibiting extracellular signal-regulated kinase 1 and 2 (ERK1/2) [